Serum CA 125 is an independent prognostic factor in cervical adenocarcinoma

American Journal of Obstetrics and Gynecology

Volumn 189, Issue 1, 2003, Pages 113-117

  Bender, David P ^a   Sorosky, Joel I ^a   Buller, Richard E ^a   Sood, Anil K ^a,b  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adenocarcinoma of the cervix; Prognostic significance; Serum CA 125

Indexed keywords

CA 125 ANTIGEN;

ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PARAAORTIC LYMPH NODE; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SURVIVAL TIME; UTERINE CERVIX; UTERINE CERVIX CARCINOMA;

EID: 0037660808     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/mob.2003.443     Document Type: Article

References (25)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47.
2. Lagasse LD, Creasman WT, Shingleton HM, Ford JH, Blessing JA. Results and complications of operative staging in cervical cancer: experience of the gynecologic oncology group. Gynecol Oncol 1980;9:90-8.
3. Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinomas relative to squamous carcinomas of the uterine cerxix-a 24-year population based study. Gynecol Oncol 2000;78:97-105.
4. Bast RC, Klug TL, St. John E, Jenison E, Niloff J, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883-7.
5. Patsner B, Mann WJ. The value of preoperative serum CA 125 levels in patients with a pelvic mass. Am J Obstet Gynecol 1988;159:873-6.
6. Cooper BC, Sood AK, Davis C, Ritchie JM, Sorosky JI, Anderson B, et al. Preoperative CA125 levels: an independent prognostic factor for epithelialovarian cancer. Obstet Gynecol. 2002;100:59-64.
7. Chi DS, Venkatraman ES, Masson V, Hoskins WJ. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 2000;77:225-6.
8. Bullet RE, Berman ML, Bloss JD, Manetta A, Disaia PJ. Serum CA125 regression in epithelial ovarian cancer: correlation with reassessment findings and survival. Gynecol Oncol 1992;47:87-92.
9. Buller RE, Vasilev S, DiSaia PJ. CA 125 kinetics: a cost-effective clinical tool to evaluate clinical trial outcomes in the 1990s. Am J Obstet Gynecol 1996;174:1241-54.
10. Sood AK, Buller RE, Burger RA, Dawson JD, Sorosky JI, Berman M. Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome. Obstet Gynecol 1997;90:441-7.
11. Duk JM, De Bruijn HWA, Groenier KH, Fleuren GJ, Aalders JG. Adenocarcinoma of the uterine cervix. Cancer 1990;65:1830-7.
12. Ngan HYS, Cheung ANY, Lauder IJ, Cheng DKL, Wong LC, Ma HK. Tumour markers and their prognostic value in adenocarcinoma of the cervix. Tumour Biol 1998;19:439-44.
13. Creasman WT. New gynecologic cancer staging. Gynecol Oncol 1995;58:157-8.
14. LaPolla JP, Schlaerth JB, Gaddis O, Morrow CP. The influence of surgical staging on evaluation and treatment of patients with cervical carcinoma. Gynecol Oncol 1986;24:194-206.
15. Leminen A. Tumor markers CA 125, carcinoembryonic antigen and tumor-associated trypsin inhibitor in patients with cervical adenocarcinoma. Gynecol Oncol 1990;39:358-63.
16. Borras G, Molina R, Xercavins J, Ballesta A, Iglesias J. Tumor antigens CA 19.9, CA 125, and CEA in carcinoma of the uterine cervix. Gynecol Oncol 1995;57:205-11.
17. Tomás C, Risteli J, Risteli L, Vuori J, Kauppila A. Use of various eptihelial tumor markers and a stromal marker in the assessment of cervical carcinoma. Obstet Gynecol 1991;77:566-72.
18. Lehtovirta P, Viinikka L, Ylikorkala O. Comparison between squamous cell carcinoma-associated antigen and CA-125 in patients with carcinoma of the cervix. Gynecol Oncol 1990;37:276-8.
19. Ngan HYS, Cheung ANY, Lauder IJ, Wong LC, Ma HK. Prognostic significance of serum tumour markers in carcinoma of the cervix. Eur J Gynaecol Oncol 1996;17:512-7.
20. Alagoz T, Buller RE, Berman M, Anderson B, Manetta A, DiSaia P. What is a normal CA125 level? Gynecol Oncol 1994;53:93-7.
21. Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as a adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group Study. J Clin Oncol 1999;17:1339-48.
22. Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999;340:1137-43.
23. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:1144-53.
24. Peters WA III, Liu PY, Barrett RJ II, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000;18:1606-13.
25. Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL III, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999;340:1154-61.